Perspective Entire Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or immediately after 3 or